NCT02401048View on ClinicalTrials.gov

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Diffuse Large B-Cell LymphomaFollicular Lymphoma
Interventions
DRUG

Ibrutinib

DRUG

MEDI4736

Trial Locations (11)

19104

Site-0402, Philadelphia

33136

Site-0388, Miami

35294

Site-0397, Birmingham

48109

Site-0729, Ann Arbor

48201

Site-0130, Detroit

60637

Site-0126, Chicago

91010

Site-0047, Duarte

94305

Site-0038, Stanford

98104

Site-0114, Seattle

02114

Site-0020/0173, Boston

07601

Site-0343, Hackensack

Sponsors

Lead Sponsor

Pharmacyclics LLC.

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Pharmacyclics LLC.

INDUSTRY